BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Rating) CEO Neil Kumar sold 120,000 shares of the stock in a transaction that occurred on Thursday, January 5th. The shares were sold at an average price of $7.67, for a total value of $920,400.00. Following the completion of the sale, the chief executive officer now directly owns 1,492,722 shares of the company's stock, valued at approximately $11,449,177.74. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Neil Kumar also recently made the following trade(s):
Get
BridgeBio Pharma alerts:
- On Thursday, November 17th, Neil Kumar sold 34,640 shares of BridgeBio Pharma stock. The shares were sold at an average price of $9.40, for a total value of $325,616.00.
BridgeBio Pharma Price Performance
Shares of BridgeBio Pharma stock opened at $7.39 on Monday. The company has a market capitalization of $1.10 billion, a price-to-earnings ratio of -2.20 and a beta of 0.62. The business has a fifty day simple moving average of $8.91 and a two-hundred day simple moving average of $9.84. BridgeBio Pharma, Inc. has a 1 year low of $4.98 and a 1 year high of $15.40.
BridgeBio Pharma (NASDAQ:BBIO – Get Rating) last posted its quarterly earnings data on Thursday, November 3rd. The company reported ($0.93) earnings per share for the quarter, topping the consensus estimate of ($1.02) by $0.09. The firm had revenue of $0.34 million for the quarter, compared to the consensus estimate of $6.26 million. As a group, equities analysts anticipate that BridgeBio Pharma, Inc. will post -3.89 earnings per share for the current fiscal year.
Analyst Ratings Changes
Separately, JPMorgan Chase & Co. cut their price target on BridgeBio Pharma from $20.00 to $19.00 and set an "overweight" rating for the company in a report on Friday, November 18th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $23.00.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in the company. Kore Private Wealth LLC increased its position in BridgeBio Pharma by 2.6% during the 3rd quarter. Kore Private Wealth LLC now owns 39,243 shares of the company's stock worth $390,000 after buying an additional 1,000 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in BridgeBio Pharma by 6.9% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 24,878 shares of the company's stock valued at $247,000 after purchasing an additional 1,613 shares in the last quarter. Martingale Asset Management L P raised its stake in BridgeBio Pharma by 4.3% in the third quarter. Martingale Asset Management L P now owns 41,375 shares of the company's stock valued at $412,000 after purchasing an additional 1,694 shares in the last quarter. Arizona State Retirement System raised its stake in BridgeBio Pharma by 13.1% in the second quarter. Arizona State Retirement System now owns 18,001 shares of the company's stock valued at $163,000 after purchasing an additional 2,086 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its stake in BridgeBio Pharma by 16.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 14,589 shares of the company's stock valued at $145,000 after purchasing an additional 2,091 shares in the last quarter. Institutional investors own 96.46% of the company's stock.
BridgeBio Pharma Company Profile
(Get Rating)
BridgeBio Pharma, Inc engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
Featured Articles
- Get a free copy of the StockNews.com research report on BridgeBio Pharma (BBIO)
- Is Goldman Sachs as Good as Gold in Your Portfolio?
- Will LI Auto Be the Least Hated Chinese EV Stock in 2023?
- Here's Why Snap Stock Can Double in 2023
- Which Streaming Service Stock is Best in 2023?
- MarketBeat: Week in Review 01/02-01/06
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
